Dr Luc-André GRANIER, MD, PhD, is a professional of the pharmaceutical industry with more than 30 years experiences, working in pharmaceutical drug development and interaction with Regulatory Agencies (FDA & EMA). Dr Luc-André Granier co-founded Advicenne in 2007 with Caroline Roussel and was the company’s CEO, Chairman and Medical Director until 2020. He is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system, and brings to PannTheraPi more than thirty years of experience in the pharmaceutical and biotech industries. In his work with companies such as Eli Lilly and Company, Synt:em and Forenap, Luc-André has overseen a number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, primarily in the areas of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. Luc-André holds Doctor of Medicine and Doctor of Science degrees from Louis Pasteur University (Strasbourg, France), where he specialized in biochemistry, and molecular and cellular biology. He is a member of several national and international scientific societies in the fields of pain, epilepsy and renal diseases. During his career
Advicenne is a company dedicated to develop medications to treat rare diseases in the field of child neurology and child nephrology. Advicenne was listed on Euronext Paris (ADVIC) on December 2017 and subsequently co listed on Euronext Brussels on June 2019.
In 2020 Dr GRANIER founded Averoa pharma Ltd, a company dedicated to develop product for renal and metabolic disease In 2021 Dr GRANIER with Dr Elsa Brillaud, Dr Gilles Huberfeld, MD, PhD and Nathalie Rouach, PhD, co-founded PannTheraPi Pharma a biotechnology company dedicated to the development of medication treating diseases through acting on blocking Pannexin
Born in 1964, Buenos Aires (Argentina)
D.E.S.S. de Psychopathologie et de Psychologie Clinique (Paris VII, Pierre et Marie Curie)
Mario Sanchez is an active clinical psychologist since 1992.
He develops his studies and his entire career in Europe (France-Switzerland).
Since 2017, he has created ties with the Dominican Republic, where he chooses residence and where he moves his clinical and research activities.
Throughout his clinical career he worked at the Paris Public Hospitals (APHP; Hôpitaux St. Antoine, Laênnec and Georges Pompidou).
He was one of the promoters and the head of the service of the first private addiction unit in France, during the first 10 years of its existence – the Clinique Montevideo, in Boulogne-Billancourt. After having worked mainly in the domain of addictions, he continued his clinical path towards Neurodevelopmental disorders (ADD, ASD and others), directing his research towards pharmacological therapy that could solve the situation of patients suffering from executive dysfunctions – often the percussion of addiction situations.
He directs clinical studies int the Dominican Republic since 2019 and he is actively working on two next studies in 2021/2022 (in Santo Domingo and soon in Santiago de los Caballeros), particularly to improve the proposed treatments in Attention Deficit (ADD), autism (ASD) and other situations consequent to executive dysfunction and non-stimulant therapies.
Since 2012, it has been promoting research activity privately, with external collaborations with university laboratories and public institutions.
He is currently a member of IDESIP (Dominican Institute for the Study of Comprehensive Health and Applied Psychology, Santo Domingo).
In 2018 he founded of CEDITRAN (Center for the Diagnosis and Treatment of Neurodevelopmental Disorders) in Santo Domingo, DR.
Mario Sanchez is an active clinical psychologist since 1992. He develops his studies and his entire career in Europe (France-Switzerland). Since 2017, he has created ties with the Dominican Republic, where he chooses residence and where he moves his clinical and research activities.
Throughout his clinical career he worked at the Paris Public Hospitals (APHP; Hôpitaux St. Antoine, Laênnec and Georges Pompidou).
He was one of the promoters and the head of the service of the first private addiction unit in France, during the first 10 years of its existence – the Clinique Montevideo, in Boulogne-Billancourt. After having worked mainly in the domain of addictions, he continued his clinical path towards Neurodevelopmental disorders (ADD, ASD and others), directing his research towards pharmacological therapy that could solve the situation of patients suffering from executive dysfunctions – often the percussion of addiction situations.
He directs clinical studies int the Dominican Republic since 2019 and he is actively working on two next studies in 2021/2022 (in Santo Domingo and soon in Santiago de los Caballeros), particularly to improve the proposed treatments in Attention Deficit (ADD), autism (ASD) and other situations consequent to executive dysfunction and non-stimulant therapies.
Since 2012, it has been promoting research activity privately, with external collaborations with university laboratories and public institutions. He is currently a member of IDESIP (Dominican Institute for the Study of Comprehensive Health and Applied Psychology, Santo Domingo). In 2018 he founded of CEDITRAN (Center for the Diagnosis and Treatment of Neurodevelopmental Disorders) in Santo Domingo, DR.
